Lipid-lowering therapy in patients with peripheral arterial disease
- Resource Type
- Authors
- Christopher J. Wolf; Jahandar Saleh; Nitin Wadhani; Edward J. Toggart; Atman P. Shah; Baubac Hayatdavoudi; Ramin Ebrahimi
- Source
- Journal of cardiovascular pharmacology and therapeutics. 9(4)
- Subject
- medicine.medical_specialty
Arterial disease
Hyperlipidemias
Disease
030204 cardiovascular system & hematology
Coronary Angiography
Asymptomatic
Lipid-lowering therapy
03 medical and health sciences
0302 clinical medicine
Risk Factors
Internal medicine
medicine
Humans
Pharmacology (medical)
In patient
Pharmacology
Peripheral Vascular Diseases
Vascular disease
business.industry
medicine.disease
Symptomatic relief
Peripheral
Surgery
Treatment Outcome
Cardiovascular Diseases
Cardiology
Quality of Life
medicine.symptom
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cardiology and Cardiovascular Medicine
business
030217 neurology & neurosurgery
- Language
- ISSN
- 1074-2484
Peripheral arterial disease (PAD) is a prevalent, chronic, and progressive atherosclerotic disease process involving the conduit vessels of the extremities. Most patients who present with objective signs of PAD are asymptomatic. These patients are at an increased risk of dying from cardiovascular events. Lipid management is the mainstay of risk-factor modification for patients with cardiovascular disease. Some evidence suggests that hypocholesterolemic drugs may halt the progression of atherosclerotic peripheral vascular disease. More recently, treatment with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors have demonstrated improved function in patients with symptomatic peripheral vascular disease. This paper reviews the role of lipid therapy in patients with peripheral arterial disease with focus on functional improvement and symptomatic relief based on the available data.